Alcon
ALC
63.00
-0.19
-0.30%
Alcon
US · ALC
#656 by market cap
Listed 1970
63.00
-0.19
-0.30%
Live - 5344 symbols - heartbeat 122s ago
· 2026-10-08 06:49
Pre-market
62.23
-1.22%
After-hours
63.00
0.00%
Overnight
62.30
-1.11%
- Market cap
- 30.45B
- P/E (TTM)i
- 48.09
- P/Bi
- 1.41
- EPSi
- 1.98
- Div yieldi
- 0.56%
- 52W posi
- 5%
Reader sentiment
Are you bullish or bearish on ALC?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Latest year +4.94% YoY
Margins
- Gross margin
- 55.24%
- Operating margin
- 13.08%
- Net margin
- 9.42%
Key ratios & quality
- PEG ratioi
- 1.12
PEG uses trailing P/E against the 3-year net income growth rate (43.02%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG."
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.15B | 7.51B | 6.83B | 8.29B | 8.72B | 9.46B | 9.91B | 10.40B |
| Gross profit | 3.19B | 3.66B | 2.94B | 4.65B | 4.75B | 5.25B | 5.51B | 5.75B |
| Selling & admin expenses | 2.80B | 2.85B | 2.69B | 3.08B | 3.07B | 3.21B | 3.25B | 3.45B |
| Research & development | 587.00M | 656.00M | 673.00M | 842.00M | 702.00M | 828.00M | 876.00M | 990.00M |
| Operating profit | -248.00M | -187.00M | -482.00M | 580.00M | 672.00M | 1.04B | 1.41B | 1.36B |
| Pretax profit | -300.00M | -332.00M | -635.00M | 418.00M | 463.00M | 832.00M | 1.26B | 1.16B |
| Tax | -73.00M | 324.00M | -104.00M | 42.00M | 128.00M | -142.00M | 238.00M | 180.00M |
| Net profit | -227.00M | -656.00M | -531.00M | 376.00M | 335.00M | 974.00M | 1.02B | 980.00M |
| Basic EPS | 0 | -1 | -1 | 1 | 1 | 2 | 2 | 2 |
| Diluted EPS | -0.46 | -1.34 | -1.09 | 0.76 | 0.68 | 1.96 | 2.05 | 1.98 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.47B | 2.60B | 2.61B | 2.72B | 2.71B | 2.82B |
| Gross profit | 1.38B | 1.39B | 1.46B | 1.52B | 1.53B | 1.68B |
| Selling & admin expenses | 813.00M | 870.00M | 865.00M | 901.00M | 882.00M | 964.00M |
| Research & development | 222.00M | 245.00M | 250.00M | 273.00M | 245.00M | 663.00M |
| Operating profit | 468.00M | 247.00M | 332.00M | 313.00M | 292.00M | 11.00M |
| Pretax profit | 414.00M | 199.00M | 283.00M | 264.00M | 240.00M | -46.00M |
| Tax | 64.00M | 23.00M | 46.00M | 47.00M | 51.00M | -46.00M |
| Net profit | 350.00M | 176.00M | 237.00M | 217.00M | 189.00M | 0 |
| Basic EPS | 1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.70 | 0.35 | 0.48 | 0.44 | 0.39 | 0.00 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 3.40B | 4.24B | 4.99B | 5.39B | 5.19B | 5.65B | 6.31B | 6.45B |
| Cash & ST investments | 258.00M | 855.00M | 1.57B | 1.58B | 980.00M | 1.10B | -- | -- |
| Inventory | 1.44B | 1.51B | 1.64B | 1.90B | 2.11B | 2.32B | 2.27B | 2.39B |
| Total assets | 27.06B | 27.66B | 27.60B | 28.00B | 29.17B | 29.61B | 30.35B | 31.56B |
| Total current liabilities | 1.89B | 2.30B | 2.26B | 2.47B | 2.74B | 2.40B | 2.28B | 3.05B |
| Short-term debt | 47.00M | 306.00M | 232.00M | 174.00M | 168.00M | 124.00M | -- | -- |
| Long-term debt | -- | 3.22B | 3.95B | 3.97B | 4.54B | 4.68B | -- | -- |
| Total liabilities | 4,423,000,000.00 | 8,352,000,000.00 | 8,778,000,000.00 | 8,743,000,000.00 | 9,488,000,000.00 | 8,990,000,000.00 | 30,347,000,000.00 | 31,555,000,000.00 |
| Total equity | 22.64B | 19.30B | 18.82B | 19.26B | 19.68B | 20.62B | -- | -- |
| Retained earnings | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 6.07B | 6.31B | 6.33B | 6.45B | 6.62B | 6.62B |
| Cash & ST investments | 1.41B | 1.41B | 1.50B | -- | 1.66B | 1.46B |
| Inventory | 2.34B | 2.39B | 2.43B | 2.39B | 2.44B | 2.51B |
| Total assets | 31.01B | 31.39B | 31.52B | 31.56B | 31.62B | 31.10B |
| Total current liabilities | 2.25B | 2.42B | 2.99B | 3.05B | 3.00B | 3.17B |
| Short-term debt | 177.00M | 147.00M | 647.00M | -- | 648.00M | 648.00M |
| Long-term debt | 4.60B | 4.66B | 4.16B | -- | 4.16B | 4.15B |
| Total liabilities | 8,989,000,000.00 | 9,257,000,000.00 | 9,436,000,000.00 | 31,555,000,000.00 | 9,486,000,000.00 | 9,502,000,000.00 |
| Total equity | 22.02B | 22.13B | 22.09B | -- | 22.13B | 21.60B |
| Retained earnings | -- | -- | -- | -- | -- | -- |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.14B | 920.00M | 823.00M | 1.35B | 1.22B | 1.39B | 2.08B | 2.27B |
| Depreciation & amortization | 1.62B | 1.43B | 1.62B | 1.22B | 1.12B | 1.22B | 1.23B | 1.34B |
| Free cash flow | 428.00M | 244.00M | 256.00M | 165.00M | 472.00M | 537.00M | 1.41B | 1.61B |
| Dividends paid | -- | 0 | 0 | -54.00M | -100.00M | -116.00M | -130.00M | -166.00M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | 0 | 0 | -676.00M |
| Ending cash balance | 227.00M | 822.00M | 1.56B | 1.58B | 980.00M | 1.09B | 1.68B | 1.53B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 384.00M | 505.00M | 724.00M | 658.00M | 418.00M | 510.00M |
| Depreciation & amortization | 310.00M | 362.00M | 187.00M | 476.00M | 322.00M | 793.00M |
| Free cash flow | 244.00M | 372.00M | 535.00M | 457.00M | 227.00M | 370.00M |
| Dividends paid | -- | -- | 0 | 0 | -- | -- |
| Stock buybacks / issuance | 0 | -116.00M | -253.00M | -307.00M | -75.00M | -278.00M |
| Ending cash balance | 1.41B | 1.41B | 1.50B | 1.53B | 1.58B | 1.36B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -1.48 | -3.38 | -2.79 | 1.97 | 1.72 | 4.83 | 4.83 | 4.50 |
| ROA %i | -1.15 | -2.39 | -1.92 | 1.35 | 1.17 | 3.31 | 3.40 | 3.17 |
| ROIC %i | -0.95 | -2.47 | -1.86 | 2.05 | 1.73 | 4.32 | 4.22 | 4.45 |
| 5-year avg ROE %i | -- | -- | -- | -0.76 | -0.64 | 0.52 | 2.11 | 3.57 |
| EBIT margin %i | -3.92 | -2.92 | -7.48 | 6.49 | 6.85 | 10.80 | 14.61 | 13.11 |
| FCF / sales %i | 5.88 | 3.25 | 3.75 | 1.99 | 5.41 | 5.68 | 14.20 | 15.46 |
| Current ratioi | 1.80 | 1.84 | 2.21 | 2.18 | 1.90 | 2.35 | 2.77 | 2.12 |
| Quick ratioi | 1.01 | 1.15 | 1.44 | 1.37 | 1.08 | 1.34 | -- | -- |
| Debt / assetsi | 0.50 | 13.76 | 16.29 | 16.00 | 17.38 | 17.34 | 1.64 | 1.61 |
| LT debt / equityi | 0.39 | 18.12 | 22.65 | 22.36 | 24.90 | 24.30 | 1.99 | 1.95 |
| Interest coveragei | -2.26 | -1.94 | -4.12 | 4.48 | 4.46 | 5.40 | 7.54 | 6.69 |
| Revenue CAGR (3Y) %i | -- | 4.41 | 0.20 | 5.04 | 5.10 | 11.43 | 6.13 | 6.06 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 39.38 | 43.02 |
| FCF CAGR (3Y) %i | -- | -30.88 | -29.22 | -27.22 | 24.60 | 28.01 | 104.30 | 50.47 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 5.23 | 4.98 | 4.74 | 4.50 | 3.71 | 2.94 |
| ROA %i | 3.70 | 3.51 | 3.32 | 3.17 | 2.62 | 2.06 |
| ROIC %i | 4.84 | 4.65 | 4.44 | 4.45 | 3.63 | 3.04 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.43 | 14.47 | 14.18 | 13.11 | 11.22 | 8.75 |
| FCF / sales %i | 14.61 | 14.11 | 13.55 | 15.46 | 14.96 | 14.63 |
| Current ratioi | 2.70 | 2.60 | 2.12 | 2.12 | 2.20 | 2.09 |
| Quick ratioi | 1.46 | 1.41 | 1.15 | -- | 1.22 | 1.12 |
| Debt / assetsi | 16.78 | 16.73 | 16.62 | 1.61 | 16.61 | 17.03 |
| LT debt / equityi | 22.84 | 23.08 | 20.79 | 1.95 | 20.81 | 21.52 |
| Interest coveragei | 7.81 | 7.37 | 7.26 | 6.69 | 5.76 | 4.55 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Surgical is the largest reported line at 55.61% of revenue, across 3 reported segments.
- Vision Care follows at 42.93%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Surgical55.61%
Vision Care42.93%
Other revenues1.45%
Quote time 2026-10-08 06:49:11 · For reference only, not investment advice and not tailored to your situation.